Eagle Pharmaceuticals Inc buy klostergang
Start price
23.06.15
/
50%
€77.64
Target price
23.12.15
€95.00
Performance (%)
9.73%
End price
23.12.15
€85.20
Summary
This prediction ended on 23.12.15 with a price of €85.20. With a performance of 9.73%, the BUY prediction by klostergang for Eagle Pharmaceuticals Inc closed with a slight gain. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Eagle Pharmaceuticals Inc | - | - | - | - |
| iShares Core DAX® | 0.985% | 8.314% | 7.032% | 49.791% |
| iShares Nasdaq 100 | 2.067% | 16.765% | 35.952% | 96.632% |
| iShares Nikkei 225® | 2.270% | 15.605% | 46.568% | 69.047% |
| iShares S&P 500 | 1.043% | 11.077% | 26.456% | 68.087% |
Comments by klostergang for this prediction
In the thread Eagle Pharmaceuticals Inc diskutieren
Fly like :
- Eagle Pharmaceuticals (NASDAQ:EGRX) submits a New Drug Application (NDA) to the FDA for a stable liquid intravenous formulation (ready-to-use or RTU) of bivalirudin for the treatment of patients undergoing percutaneous coronary intervention (PCI) in the following scenarios: with the use of a glycoprotein IIb/IIIa inhibitor or at risk of heparin-induced thrombocytopenia and thrombosis syndrome and patients with unstable angina undergoing percutaneous transluminal coronary angioplasty.
- RTU bivalirudin, intended for use with aspirin, contains the same active ingredient as The Medicines Company's (NASDAQ:MDCO) Angiomax (bivalirudin), but eliminates the need for reconstitution/dilution.
- Angiomax generated ~$600M in sales in 2014.
- Bivalirudin is an anticoagulant that inhibits thrombin.
(Laufzeit überschritten)